Overview
OSE Immunotherapeutics is a Nantes-based clinical-stage biotech company developing immunotherapy candidates for cancer and autoimmune diseases — two therapeutic areas where the immune system is the central battleground, and where France 2030’s health innovation investments are building a French biotech ecosystem competitive with the established US and Swiss immunotherapy leaders. Founded in 2012 through the merger of two French biotech companies (OSE Pharma and Effimune), OSE Immunotherapeutics has built a differentiated portfolio targeting multiple points of immune system modulation, from checkpoint inhibitors to regulatory T cell modulation — with the specific ambition of going beyond the first generation of checkpoint inhibitors (anti-PD-1, anti-CTLA-4) that have dominated cancer immunotherapy since 2011.
OSE Immunotherapeutics is listed on Euronext Paris, giving it capital market access while maintaining the French identity and clinical development relationships that make it a participant in France 2030’s biotech ecosystem. The company’s approach to immunotherapy development is explicitly differentiated from the major checkpoint inhibitor programs: OSE focuses on immune targets and mechanisms that address resistance to existing checkpoint inhibitors (a limitation affecting approximately 60-80% of patients treated with current checkpoint therapies) and on autoimmune conditions where immune over-activation rather than suppression is the clinical challenge.
The Nantes location is significant. The Pays de la Loire region hosts several major French biotech and pharmaceutical research programs, and Nantes University Hospital (CHU de Nantes) provides access to one of France’s most active clinical research centers for immunology and oncology. The region’s commitment to biotech innovation, partly supported by France 2030 regional investment, has created an ecosystem that supports companies like OSE Immunotherapeutics through talent access, clinical trial infrastructure, and proximity to academic immunology research.
France 2030 Funding & Projects
OSE Immunotherapeutics’ France 2030 engagement occurs primarily through the health innovation and oncology research funding mechanisms that support clinical-stage biotech companies developing novel cancer treatments. Bpifrance has historically provided non-dilutive funding support (repayable advances and grants) for OSE’s clinical programs — a critical mechanism for French biotech companies that need to fund expensive Phase 1 and Phase 2 clinical trials without full dependence on dilutive equity raises.
The ANR and INCa (Institut National du Cancer) provide research grant funding for collaborative projects between OSE and French academic immunology centers, including work on biomarker identification (determining which patients are most likely to respond to specific immunotherapy approaches) and combination strategy development. France 2030’s investment in clinical trial infrastructure — including the UNICANCER network of comprehensive cancer centers and the French national oncology biomarker program — creates the accelerated trial enrollment capabilities that reduce the time and cost of clinical development for companies like OSE.
The France 2030 bioproduction sovereignty agenda also touches OSE: developing French manufacturing capability for biological drugs — including the antibody and antibody-fragment therapeutics that OSE’s clinical portfolio includes — is a France 2030 health objective that benefits from the CDMO capacity expansion (Novasep, Yposkesi, and others) that France 2030 supports.
Strategic Position
OSE Immunotherapeutics competes in one of the most competitive segments of pharmaceutical development: cancer immunotherapy, where Bristol-Myers Squibb (Opdivo/Yervoy), Merck (Keytruda), Roche/Genentech (Atezolizumab), and dozens of clinical-stage competitors are pursuing related mechanisms with substantially greater capital. The strategic rationale for OSE’s approach is differentiation: targeting immune mechanisms beyond PD-1/CTLA-4 that address resistant tumors and patient populations who do not respond to existing checkpoint inhibitors.
OSE’s clinical pipeline includes candidates targeting SIRPα (a myeloid checkpoint that prevents macrophages from engulfing tumor cells — an immune evasion mechanism that PD-1 inhibitors do not address), Siglec-6 (another myeloid immune checkpoint), and FR804 (a first-in-class candidate targeting immune regulatory T cells in autoimmune conditions). Each target represents a scientific hypothesis about immune mechanisms that established therapies do not address, with clinical proof-of-concept required to validate the approach before a partnership or licensing deal becomes available from large pharmaceutical companies.
Key Technology & Innovation
OSE Immunotherapeutics’ scientific platform draws on deep immunological expertise at the intersection of cancer immunology and autoimmunity — a combination that reflects the recognition that the same immune mechanisms (T regulatory cells, myeloid suppressor cells, immune checkpoints) that tumors exploit to avoid immune destruction are also dysregulated in autoimmune diseases. This dual relevance — targeting the same biological pathway in cancer (where immune activation is desired) and autoimmunity (where immune suppression is needed) — creates a broader clinical application portfolio from a single mechanistic investment.
The SIRPα/CD47 axis — one of OSE’s primary targets — has attracted substantial industry validation, with multiple pharmaceutical companies developing anti-CD47 antibodies targeting the same signaling pathway from the tumor cell side (where CD47 is often overexpressed as a “don’t eat me” signal). OSE’s anti-SIRPα approach targets the signaling from the macrophage side — blocking the inhibitory signal that prevents macrophages from phagocytosing tumor cells — representing a mechanistically distinct approach to the same biological problem.
Leadership
OSE Immunotherapeutics is led by Alexis Peyroles (CEO) with a scientific leadership team combining clinical development expertise and fundamental immunology research background. The company’s Nantes base and its board composition reflect the regional biotech ecosystem investment that France 2030’s decentralized innovation agenda supports — OSE is demonstrably a Nantes success story rather than a Paris-centric one, reflecting the geographic diversity of French biotech innovation.
Competitive Landscape
Within France, OSE Immunotherapeutics shares the oncology immunotherapy space with companies including Valneva (vaccines), Genfit (metabolic disease), and the oncology programs of larger French pharma groups. Internationally, the checkpoint inhibitor landscape is dominated by companies with multi-billion-dollar R&D budgets — Merck, BMS, Roche — that OSE cannot match on capital. The strategic response is differentiation: developing assets that address resistance or patient populations where the established therapies have demonstrated limitations, then partnering with large pharma for the Phase 3 development and commercialization that require major capital.
The partnering trajectory — demonstrating Phase 1/2 proof-of-concept, then licensing or partnering for later-stage development — is the standard French biotech business model, validated by multiple successful partnerships between French clinical-stage companies and large multinational pharma groups. OSE’s pipeline breadth (multiple targets, oncology and autoimmune) provides multiple shots at achieving the partnership-enabling data package.
Investor Perspective
OSE Immunotherapeutics’ Euronext Paris listing (OSE) gives biotech investors direct exposure to French immunotherapy innovation at a valuation typically reflecting the clinical stage and binary nature of drug development risk. The company’s pipeline diversity — multiple targets across oncology and autoimmunity — provides multiple potential catalysts (clinical trial data readouts) that could drive valuation changes, positive or negative.
France 2030’s health innovation support reduces the non-clinical development capital burden, enabling OSE to focus available capital on clinical trial execution. For investors specifically interested in French biotech, OSE represents one of the more established clinical-stage companies — with a track record of executing clinical programs and generating scientific data — in France’s growing immunotherapy ecosystem. Key risks include clinical failure at Phase 2 (inherent to all clinical-stage biotech investment) and the competitive challenge of establishing clinical differentiation against well-funded larger competitors pursuing adjacent targets.
Related Companies
- Nanobiotix — French cancer therapy innovation
- Valneva — French vaccine and biotech
- Genfit — French clinical-stage biotech
- Sanofi — French pharma, potential partnership target
- IPsen — French oncology pharma
- DNA Script — French biotech deep tech